SSG
IOVA icon

Summit Securities Group’s Iovance Biotherapeutics IOVA Stock Holding History

Summit Securities Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,819
Closed -$7.7K – 1213
2025
Q4 		$7.7K Buy
+2,819
New +$6.52K ﹤0.01% 910
2023
Q4 		– Sell
-7,786
Closed -$35K – 784
2023
Q3 		$35K Buy
+7,786
New +$50.8K ﹤0.01% 319

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Summit Securities Group's IOVA Position: Q1 2026 in Review

Summit Securities Group sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 2,819 shares — an estimated $7.7K sold.

Summit Securities Group first reported a position in IOVA in Q3 2023 and held it in 2 quarters. The position peaked at $35K in Q3 2023. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Summit Securities Group reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 2,819 Iovance Biotherapeutics shares in Q1 2026, an estimated $7.7K.
  • Summit Securities Group first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 2 quarters.
  • Summit Securities Group's Iovance Biotherapeutics position peaked at $35K in Q3 2023.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.